Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP

Abstract Quality, traceability and reproducibility are crucial factors in the reliable manufacture of cellular therapeutics, as part of the overall framework of Good Manufacturing Practice (GMP). As more and more cellular therapeutics progress towards the clinic and research protocols are adapted to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Moyra Lawrence, Amanda Evans, Thomas Moreau, Marta Bagnati, Matthew Smart, Enas Hassan, Jahid Hasan, Monica Pianella, Julie Kerby, Cedric Ghevaert
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Acceso en línea:https://doaj.org/article/ec9c921fb0fa4a27a26eb34ffe692aee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Quality, traceability and reproducibility are crucial factors in the reliable manufacture of cellular therapeutics, as part of the overall framework of Good Manufacturing Practice (GMP). As more and more cellular therapeutics progress towards the clinic and research protocols are adapted to comply with GMP standards, guidelines for safe and efficient adaptation have become increasingly relevant. In this paper, we describe the process analysis of megakaryocyte manufacture from induced pluripotent stem cells with a view to manufacturing in vitro platelets to European GMP for transfusion. This process analysis has allowed us an overview of the entire manufacturing process, enabling us to pinpoint the cause and severity of critical risks. Risk mitigations were then proposed for each risk, designed to be GMP compliant. These mitigations will be key in advancing this iPS-derived therapy towards the clinic and have broad applicability to other iPS-derived cellular therapeutics, many of which are currently advancing towards GMP-compliance. Taking these factors into account during protocol design could potentially save time and money, expediting the advent of safe, novel therapeutics from stem cells.